What ever happened to the Jimi Hendrix brand products they were going release. Whatever happened to good old Pitsicalis? I wonder why there is no mention of this so called license in their financials.
Cannabis Science Signs Andrew Pitsicalis as International Brand and Licensing Director, Rockin Artwork Grants Cannabis Science a License to Make Jimi Hendrix Image and Likeness Related Products for Advertising, Manufacturing, Sales and Marketing
April 20, 2012
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to welcome Andrew Pitsicalis as International Brand and Licensing Director.
Mr. Pitsicalis has been CEO of Rockin Artwork since 2010. Rockin Artwork is an intellectual property company, which manages or owns images and art by artists for Licensing and Fine Art. Their works include those by Mike and Dasha Biggs, David Garibaldi, Justin Farano, Dan Kennedy and more. Leon Hendrix, Jimi Hendrix's brother, is an owner and the spiritual guide of the company and their collection includes Jimi Hendrix images and art for merchandise and licensing.
Rockin Artwork has granted Cannabis Science a co-branding license to allow Cannabis Science to advertise, manufacture, and brand Jimi Hendrix images and likenesses and to make Jimi Hendrix image and likeness related products and the marketing thereof. Leon Hendrix is pleased to endorse Cannabis Sciences’ role in creating great products his brother Jimi Hendrix would be proud of.
When asked his thoughts were joining Cannabis Science Inc., Mr. Pitsicalis said, ”I look forward to creating great quality products. Having experience licensing properties that span a fan base of 2 billion people worldwide, I have licensed products in mass market retail stores around the globe. You can find Pitsicalis’ companies, licensed products in places like, Walmart, Target, Kohls, JC Penny, Urban Outfitters, Old Navy and other mass retail chains."
Mr. Pitsicalis’s role at Cannabis Science is to help build the brands of Cannabis Science. This will include consulting and brand management of Cannabis Science product lines, manufacture and develop the licensing platform for Cannabis Science, Patents and Trademarks. Mr. Pitsicalis will facilitate the advertising and licensing of products and branding of Cannabis Science. Pitsicalis will be selecting advertising campaigns for brand and product recognition. There are plans in the future to eventually license our biotechnology to pharmaceutical companies and other hemp related manufacturing licenses. Andrew has extensive connections to doctors, intellectual property, and venues for future medical cannabis conferences, all of which are invaluable to Cannabis Science.
Mr. Pitsicalis, legal victories in Federal Court for Jimi Hendrix Intellectual property rights will give Cannabis Science a seasoned component to licensing and branding. Andrew will be seated on the Policy Advisory Board for the company and we are pleased to have his input from his legal and licensing knowledge.
Cannabis Science is excited to welcome another talented and professional individual into the fold and looks forward to the endless promotion opportunities available through Andrew Pitsicalis.
About Cannabis Science, Inc. Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Cannabis Science Inc. Dr. Robert J. Melamede President & CEO 1-888-889-0888 info@cannabisscience.com or Robert Kane Investor Relations Management 1-561-234-6929 rkane@cannabisscience.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
